SEC Comment Letter for Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354) — Aug 26, 2021
Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354)
Date: Aug. 26, 2021 · CIK: 0001035354 · Accession: 0000000000-21-010428
AI Filing Summary & Sentiment
File numbers found in text: 333-258994
Letter
United States securities and exchange commission logo August 26, 2021 Sumit Aggarwal Chief Executive Officer Eloxx Pharmaceuticals, Inc. 480 Arsenal Way Watertown, MA 02472 Re:Eloxx Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 20, 2021 File No. 333-258994 Dear Mr. Aggarwal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cara Wirth at (202) 551-7127 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Peter N. Handrinos, Esq.
Show Raw Text
United States securities and exchange commission logo
August 26, 2021
Sumit Aggarwal
Chief Executive Officer
Eloxx Pharmaceuticals, Inc.
480 Arsenal Way
Watertown, MA 02472
Re:Eloxx Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 20, 2021
File No. 333-258994
Dear Mr. Aggarwal:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cara Wirth at (202) 551-7127 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Peter N. Handrinos, Esq.